CERo Therapeutics (CERO) Competitors $0.25 0.00 (-0.40%) (As of 09:15 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsShort InterestTrends CERO vs. ATOS, DRUG, FTLF, NLTX, SGMT, ABOS, PBYI, BDTX, IVA, and IPHAShould you be buying CERo Therapeutics stock or one of its competitors? The main competitors of CERo Therapeutics include Atossa Therapeutics (ATOS), Bright Minds Biosciences (DRUG), FitLife Brands (FTLF), Neoleukin Therapeutics (NLTX), Sagimet Biosciences (SGMT), Acumen Pharmaceuticals (ABOS), Puma Biotechnology (PBYI), Black Diamond Therapeutics (BDTX), Inventiva (IVA), and Innate Pharma (IPHA). These companies are all part of the "pharmaceutical products" industry. CERo Therapeutics vs. Atossa Therapeutics Bright Minds Biosciences FitLife Brands Neoleukin Therapeutics Sagimet Biosciences Acumen Pharmaceuticals Puma Biotechnology Black Diamond Therapeutics Inventiva Innate Pharma Atossa Therapeutics (NASDAQ:ATOS) and CERo Therapeutics (NASDAQ:CERO) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, community ranking, risk, profitability, institutional ownership, media sentiment, dividends, earnings and analyst recommendations. Is ATOS or CERO more profitable? CERo Therapeutics' return on equity of 0.00% beat Atossa Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atossa TherapeuticsN/A -35.74% -33.51% CERo Therapeutics N/A N/A -114.64% Does the MarketBeat Community prefer ATOS or CERO? Atossa Therapeutics received 237 more outperform votes than CERo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformAtossa TherapeuticsOutperform Votes23764.93% Underperform Votes12835.07% CERo TherapeuticsN/AN/A Which has higher valuation and earnings, ATOS or CERO? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtossa TherapeuticsN/AN/A-$30.09M-$0.22-5.36CERo TherapeuticsN/AN/A-$2.54MN/AN/A Does the media refer more to ATOS or CERO? In the previous week, Atossa Therapeutics had 7 more articles in the media than CERo Therapeutics. MarketBeat recorded 14 mentions for Atossa Therapeutics and 7 mentions for CERo Therapeutics. Atossa Therapeutics' average media sentiment score of 0.51 beat CERo Therapeutics' score of -0.15 indicating that Atossa Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Atossa Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive CERo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do insiders & institutionals believe in ATOS or CERO? 12.7% of Atossa Therapeutics shares are held by institutional investors. Comparatively, 29.6% of CERo Therapeutics shares are held by institutional investors. 7.6% of Atossa Therapeutics shares are held by company insiders. Comparatively, 18.0% of CERo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, ATOS or CERO? Atossa Therapeutics has a beta of 1.23, meaning that its stock price is 23% more volatile than the S&P 500. Comparatively, CERo Therapeutics has a beta of -0.5, meaning that its stock price is 150% less volatile than the S&P 500. Do analysts prefer ATOS or CERO? Atossa Therapeutics currently has a consensus target price of $6.75, indicating a potential upside of 472.03%. Given Atossa Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Atossa Therapeutics is more favorable than CERo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atossa Therapeutics 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00CERo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 SummaryAtossa Therapeutics beats CERo Therapeutics on 8 of the 12 factors compared between the two stocks. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Get CERo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CERO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CERO vs. The Competition Export to ExcelMetricCERo TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$37.25M$2.93B$5.07B$8.90BDividend YieldN/A1.91%4.99%4.07%P/E RatioN/A16.1687.8613.46Price / SalesN/A282.771,228.8287.66Price / CashN/A169.3839.5136.27Price / Book-0.104.436.946.30Net Income-$2.54M-$41.63M$119.12M$225.93M7 Day Performance32.37%-4.73%-1.84%-1.32%1 Month PerformanceN/A-6.53%-3.65%0.60%1 Year PerformanceN/A25.63%31.64%26.23% CERo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CEROCERo TherapeuticsN/A$0.25-0.4%N/AN/A$37.25MN/A0.008Gap DownATOSAtossa Therapeutics1.2137 of 5 stars$1.18-1.7%$6.75+472.0%+62.2%$148.44MN/A-5.458Analyst DowngradeAnalyst RevisionGap DownDRUGBright Minds Biosciences0.8622 of 5 stars$33.25+1.8%N/A+2,513.4%$147.30MN/A0.00N/AFTLFFitLife Brands4.0645 of 5 stars$31.83+2.3%$40.00+25.7%+59.9%$146.42M$52.70M18.8320Analyst RevisionNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeSGMTSagimet Biosciences2.1861 of 5 stars$4.65+2.9%$21.60+364.5%+50.2%$142.62M$2M0.008ABOSAcumen Pharmaceuticals2.6635 of 5 stars$2.37-0.8%$9.00+279.7%+0.4%$142.39MN/A0.0051Analyst RevisionPBYIPuma Biotechnology4.4141 of 5 stars$2.89+1.8%$7.00+142.2%-27.0%$141.87M$235.60M5.92185Analyst ForecastPositive NewsBDTXBlack Diamond Therapeutics2.8436 of 5 stars$2.49+2.5%$15.50+522.5%+8.0%$140.88MN/A0.0090Positive NewsIVAInventiva3.0751 of 5 stars$2.61-4.7%$14.00+436.4%-31.9%$136.97M$18.91M0.00100News CoverageIPHAInnate Pharma2.2362 of 5 stars$1.69+13.5%$11.50+582.3%-32.8%$136.48M$66.71M0.00220News CoverageGap Up Related Companies and Tools Related Companies ATOS Alternatives DRUG Alternatives FTLF Alternatives NLTX Alternatives SGMT Alternatives ABOS Alternatives PBYI Alternatives BDTX Alternatives IVA Alternatives IPHA Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CERO) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CERo Therapeutics Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CERo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CERO Stock Alerts